PanThera Targeting Epilepsy Ictogenesis Process Through Pannexin-1 Modulation
- Coordinator
- College De France, France
- Runs
- 1 October 2022 to 31 March 2024
- Status
- Finished
- EU funding
- €150k
- Total cost
- —
- Partners
- 1 organisations in 1 countries
- Type
- European Research Council grant
- Grant agreement
- 101069281
What the project is doing
In the project's own words, from its summary on CORDIS.
Epilepsy, affecting about 1% of the population, comprises a group of neurological disorders characterized by the periodic occurrence of seizures, which disrupt normal brain function. Despite treatment with current antiepileptic drugs, one third of epileptic patients are pharmacoresistant and most patients suffer from side effects, making it crucial to develop novel therapies. Current drugs indeed target channels and receptors involved in normal brain function, not specific to the disease.
Our academic work has recently identified a novel and innovative target for epilepsy. Our project thus aims at bringing to the market a new generation of antiepileptic drugs specifically targeting the disease.
Topics
Who is involved
| Organisation | City | Country | Role |
|---|---|---|---|
| College De France | Paris | France | Coordinator |
Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI